Full Breakdown
New Research Challenges Alzheimer's Disease Paradigm: Potential for Reversal
12/25/2025, 7:43:34 PM
Breakthrough Findings on NAD+ and Alzheimer's Disease
For over a century, Alzheimer's disease (AD) has been viewed as irreversible, leading research to focus primarily on prevention and slowing progression rather than recovery. However, a recent study conducted by researchers from University Hospitals, Case Western Reserve University, and the Louis Stokes Cleveland VA Medical Center challenges this long-held belief. The study, led by Kalyani Chaubey, PhD, published in *Cell Reports Medicine*, reveals that the brain's failure to maintain normal levels of the cellular energy molecule NAD+ is a significant driver of AD. The researchers demonstrated that not only can maintaining NAD+ levels prevent the onset of AD, but restoring these levels in advanced stages can reverse the disease and restore cognitive function.
Methodology and Results
The research utilized various preclinical mouse models engineered to express genetic mutations associated with AD, specifically focusing on amyloid and tau pathologies. The study found that NAD+ levels decline significantly in the brains of both humans with AD and the mouse models. The team tested the effects of a pharmacologic agent, P7C3-A20, which helps maintain NAD+ balance. Remarkably, treatment initiated after significant disease progression led to the repair of major pathological damage and full cognitive recovery in the mice.
Implications for Future Research
These findings suggest a paradigm shift in the approach to Alzheimer's treatment, indicating that the effects of the disease may not be permanently irreversible. Andrew A. Pieper, MD, PhD, the senior author of the study, emphasized the potential for recovery, stating, “The damaged brain can, under some conditions, repair itself and regain function.” The study also identified candidate proteins in human AD brains that may relate to the ability to reverse the disease, paving the way for future clinical trials.
Criticism and Cautions
Despite the promising results, Dr. Pieper cautioned against confusing this therapeutic approach with over-the-counter NAD+ precursors, which can elevate NAD+ to harmful levels that may promote cancer. The study's method specifically utilizes P7C3-A20 to maintain healthy NAD+ levels without pushing them beyond normal ranges.
Conflicting Reports & Gaps
While the study presents a hopeful outlook on reversing Alzheimer's, it is essential to note that these findings are based on animal models. The translation of these results to human patients remains to be seen, and further research is necessary to determine the efficacy of this approach in clinical settings.
What's Next
The research opens avenues for additional studies aimed at exploring complementary strategies for Alzheimer's reversal and investigating the effectiveness of this recovery approach in other chronic, age-related neurodegenerative diseases. The technology is currently being commercialized by Glengary Brain Health, co-founded by Dr. Pieper, with plans for carefully designed human clinical trials to assess its potential in patients.
Verbatim Quotes
- “Restoring the brain's energy balance achieved pathological and functional recovery in both lines of mice with advanced Alzheimer's.” — Andrew A. Pieper, MD, PhD, Director of the Brain Health Medicines Center, Harrington Discovery Institute at UH.
- “The key takeaway is a message of hope – the effects of Alzheimer's disease may not be inevitably permanent,” — Andrew A. Pieper, MD, PhD.
- “Through our study, we demonstrated one drug-based way to accomplish this in animal models, and also identified candidate proteins in the human AD brain that may relate to the ability to reverse AD.” — Kalyani Chaubey, PhD.
